Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 9:20 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Target systolic blood pressure <140 mmHg Clear all

Conditions: Blood Pressure, End Stage Renal Disease on Dialysis (Diagnosis), Chronic Kidney Diseases, Chronic Kidney Disease Stage 5
Interventions: Anti-Hypertensive medications, Dry Weight Adjustment; Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 100 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 2
States / cities: San Francisco, California • Seattle, Washington

Conditions: Hypertension, Diastolic Dysfunction
Interventions: valsartan, amlodipine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 45 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: USA, New Jersey

Conditions: Hypertension, Hemorrhage
Interventions: clevidipine; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 14
States / cities: Washington D.C., District of Columbia • Honolulu, Hawaii • Baltimore, Maryland + 11 more

Conditions: Hypertension, Pregnancy-Induced, Hypertension, Postpartum Preeclampsia, Postpartum Complication, Postpartum Pre-Eclampsia, Cardiovascular Diseases, Cardiovascular Morbidity, Morbidity;Perinatal
Interventions: BP Watch; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Hypertension, Left Ventricular Diastolic Dysfunction
Interventions: Nebivolol; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Intracerebral Hemorrhage
Interventions: Intravenous nicardipine hydrochloride; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 116
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more

Conditions: Intracranial Hemorrhage, Hypertensive, Craniotomy Tumor Removal Surgery
Interventions: Target SBP <160mmHg, Target SBP <140 mmHg; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: End Stage Renal Disease on Dialysis
Interventions: Dry weight target adjustment, Anti-hypertensive medications; Other · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: San Francisco, California • Seattle, Washington

Conditions: Acute Cholecystitis, Chronic Cholecystitis
Interventions: TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia, TIVA - Tachycardia, INH - Hypotension, INH - Hypertension, INH - Bradycardia, INH - Tachycardia; Procedure
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke, Cerebrovascular Disease
Interventions: Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia, Hyperglycemia treatment, Do-not-resuscitate (DNR) or withdrawal of care, Referral to Intensive Care, Referral to Neurosurgery, Repeat brain imaging, Standard care; Other · Diagnostic Test
Lead sponsor: Region Skane; Other
Eligibility: 18 Years and older
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Intracerebral Hemorrhage, Hypertension, Stroke
Interventions: nicardipine; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 12
States / cities: Los Angeles, California • Kansas City, Kansas • Boston, Massachusetts + 8 more

Conditions: End Stage Kidney Disease (ESKD), Hypertension (HTN), Peritoneal Dialysis (PD)
Interventions: Target systolic blood pressure <120 mmHg., Target systolic blood pressure <140 mmHg; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: San Francisco, California

Conditions: Hypertension, Metabolic Syndrome
Interventions: Aliskerin/Valsartan and Rampiril; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Acute Stroke, Endovascular Thrombectomy
Interventions: Nicardipine, Labetalol, Hydralazine; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Hartford, Connecticut • Cincinnati, Ohio • Nashville, Tennessee

Search by objective public record fields.

Blood Pressure Lowering in Dialysis (BOLD) Trial

The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction

Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)

Wearables to Define Postpartum Blood Pressure Trajectories and Facilitate Evidence-based Monitoring Guidelines

Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart

Antihypertensive Treatment of Acute Cerebral Hemorrhage-II

Comparison of Post-Craniotomy Blood Pressure Targets

The Home Blood Pressure (BP) Trial

Evaluation of Closed-loop TIVA Propofol, Sufentanil and Ketamine Guided by BIS Monitor

International Care Bundle Evaluation in Cerebral Hemorrhage Research

Antihypertensive Treatment in Acute Cerebral Hemorrhage

Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome

Blood Pressure After Endovascular Stroke Therapy-II